RespireRx Pharmaceuticals, Inc. (RSPI)
| Market Cap | 1.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.17M |
| Shares Out | 119.59M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Open | 0.0084 |
| Previous Close | 0.0088 |
| Day's Range | 0.0084 - 0.0084 |
| 52-Week Range | 0.0031 - 0.0330 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RSPI
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program... [Read more...]
Financial Performance
Financial StatementsNews
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep A...
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by Cu...
Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tre...
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAki...
Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compoun...
Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...
RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures an...
Glen Rock, N.J., March 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmac...
Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary tr...
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary treatm...
RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Developm...
Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary ...
RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81
Glen Rock, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary ...
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Tr...
Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...
RespireRx Pharmaceuticals Inc. Announces CEO's OTC Venture Market Podcast
Glen Rock, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary ...
RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO
Glen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary ...
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
Glen Rock, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolut...
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal C...
Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary t...
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary...
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the OTC...